Adelaide Research & Scholarship: Search

Search

Results 1-6 of 6 (Search time: 0.003 seconds).

Item hits:

Issue Date	Title	Author(s)
2004	Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation	Mullighan, C.; Heatley, S.; Doherty, K.; Szabo, F.; Grigg, A.; Hughes, T.; Schwarer, A.; Szer, J.; Tait, B.; To, L.; Bardy, P.
2005	In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.	White, D.; Saunders, V.; Lyons, A.; Branford, S.; Grigg, A.; To, L.; Hughes, T.
2008	Long-term imatinib therapy promotes bone formation in CML patients	Fitter, S.; Dewar, A.; Kostakis, P.; To, L.; Hughes, T.; Roberts, M.; Lynch, K.; Vernon-Roberts, B.; Zannettino, A.
2006	Imatinib as a potential antiresorptive therapy for bone disease	Dewar, A.; Farrugia, A.; Condina, M.; To, L.; Hughes, T.; Vernon-Roberts, B.; Zannettino, A.
2004	Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations	Branford, S.; Rudzki, Z.; Parkinson, I.; Grigg, A.; Taylor, K.; Seymour, J.; Durrant, S.; Browett, P.; Schwarer, A.; Arthur, C.; Catalano, J.; Leahy, M.; Filshie, R.; Bradstock, K.; Herrmann, R.; Joske, D.; Lynch, K.; Hughes, T.
2007	Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia	White, D.; Saunders, V.; Grigg, A.; Arthur, C.; Filshie, R.; Leahy, M.; Lynch, K.; To, L.; Hughes, T.